Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Assembly Biosciences, Inc is a biotechnology business based in the US. Assembly Biosciences shares (ASMB) are listed on the NASDAQ and all prices are listed in US Dollars. Assembly Biosciences employs 139 staff and has a trailing 12-month revenue of around USD$52.5 million.
Since the stock market crash in March caused by coronavirus, Assembly Biosciences's share price has had significant negative movement.
Its last market close was USD$5.62, which is 73.53% down on its pre-crash value of USD$21.23 and 82.03% down on the lowest point reached during the March crash when the shares fell as low as USD$10.23.
If you had bought USD$1,000 worth of Assembly Biosciences shares at the start of February 2020, those shares would have been worth USD$798.53 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$306.12.
|Latest market close||USD$5.62|
|52-week range||USD$10.23 - USD$25.78|
|50-day moving average||USD$17.0646|
|200-day moving average||USD$19.8907|
|Wall St. target price||USD$43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.664|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||0.18%|
|1 month (2020-10-23)||-62.21%|
|3 months (2020-08-25)||-73.86%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-25)||-62.73%|
|2 years (2018-11-23)||-77.78%|
|3 years (2017-11-24)||-86.97%|
|5 years (2015-11-25)||-42.06%|
|Revenue TTM||USD$52.5 million|
|Gross profit TTM||USD$-69,794,000|
|Return on assets TTM||-17.27%|
|Return on equity TTM||-32.35%|
|Market capitalisation||USD$510.9 million|
TTM: trailing 12 months
There are currently 3.9 million Assembly Biosciences shares held short by investors – that's known as Assembly Biosciences's "short interest". This figure is 4.3% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting Assembly Biosciences shares can be evaluated.
Assembly Biosciences's "short interest ratio" (SIR) is the quantity of Assembly Biosciences shares currently shorted divided by the average quantity of Assembly Biosciences shares traded daily (recently around 294362.71963331). Assembly Biosciences's SIR currently stands at 13.09. In other words for every 100,000 Assembly Biosciences shares traded daily on the market, roughly 13090 shares are currently held short.
However Assembly Biosciences's short interest can also be evaluated against the total number of Assembly Biosciences shares, or, against the total number of tradable Assembly Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Assembly Biosciences's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Assembly Biosciences shares in existence, roughly 120 shares are currently held short) or 0.1213% of the tradable shares (for every 100,000 tradable Assembly Biosciences shares, roughly 121 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Assembly Biosciences.
Find out more about how you can short Assembly Biosciences stock.
We're not expecting Assembly Biosciences to pay a dividend over the next 12 months.
Assembly Biosciences's shares were split on a 1:5 basis on 14 July 2014. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assembly Biosciences shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Assembly Biosciences shares which in turn could have impacted Assembly Biosciences's share price.
Over the last 12 months, Assembly Biosciences's shares have ranged in value from as little as $10.23 up to $25.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assembly Biosciences's is 1.203. This would suggest that Assembly Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.